compass pathways Archives | Psychedelic Spotlight

Petitioning the DEA to respect the ‘Right to Try Laws’ which empower terminally ill patients to legally access psilocybin therapy.

Psilocybin showed rapid antidepressant effects for most patients, but only 1 in 5 participants showed significant improvement at 12 weeks

Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics

If you want to invest in psychedelic stocks, ignore the hype and look at the technicals. We take a deep dive on atai Life Sciences & COMPASS Pathways

Cathie Wood is buying up stocks from the most dubious actors in the psychedelic sector. Given ARK Invest’s subpar performance, is that a good thing?

Compass Pathways faces a legal challenge from Terran Biosciences over the potential theft of intellectual property

The road to psychedelic legalization has many paths. These 3 clinical trials have the best chances to legalize psychedelics for therapy

Compass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research

George Goldsmith will be replaced as Compass Pathways CEO. Is this good or bad news?

Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin.